Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

D. Doroshow · SciRah

Researcher profile · Semantic Scholar

D. Doroshow

Share profile

D. Doroshow — researcher profile on SciRah

h-index: 17
Works: 75
Citations: 4,554

Most-cited papers

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
N. Kuderer, T. Choueiri, D. Shah, Y. Shyr +232 more
2020The Lancet1,565 citations Open access
Semantic Scholar
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
D. Doroshow, S. Bhalla, M. Beasley, L. Sholl +6 more
2021Nature Reviews Clinical Oncology1,356 citations
Semantic Scholar
Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes
D. Doroshow, M. Sanmamed, K. Hastings, K. Politi +5 more
2019Clinical Cancer Research532 citations Open access
Semantic Scholar
BET inhibitors: a novel epigenetic approach
D. Doroshow, J. P. Eder, Patricia M. Lorusso
2017Annals of Oncology341 citations Open access
Semantic Scholar
Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: A COVID-19 and Cancer Consortium (CCC19) cohort study
D. Rivera, S. Peters, O. Panagiotou, D. Shah +41 more
2020Cancer Discovery122 citations Open access
Semantic Scholar
Treatment of Advanced Non-Small Cell Lung Cancer in 2018.
D. Doroshow, R. Herbst
2018JAMA Oncology94 citations
Semantic Scholar
Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations)
H. Mahdi, Navid Hafez, D. Doroshow, D. Sohal +12 more
2021JCO Precision Oncology65 citations Open access
Semantic Scholar
Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study
A. Schmidt, Z. Bakouny, S. Bhalla, J. Steinharter +25 more
2020Cancer Cell65 citations Open access
Semantic Scholar
Survey of the Impact of COVID-19 on Oncologists’ Decision Making in Cancer
Y. Ürün, S. Hussain, Z. Bakouny, D. Castellano +12 more
2020JCO Global Oncology38 citations Open access
Semantic Scholar
Clinical Efficacy of Olaparib in IDH1/IDH2-Mutant Mesenchymal Sarcomas
J. Eder, D. Doroshow, K. Do, V. Keedy +4 more
2021JCO Precision Oncology34 citations Open access
Semantic Scholar
Genomics and the History of Precision Oncology
D. Doroshow, J. Doroshow
2019Surgical Oncology Clinics of North America33 citations Open access
Semantic Scholar
Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study
Z. Bakouny, C. Labaki, S. Bhalla, A. Schmidt +32 more
2022Annals of Oncology30 citations Open access
Semantic Scholar
A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance
M. Abidi, D. Aboulafia, M. Accordino, J. Acoba +278 more
2020Cancer Cell26 citations Open access
Semantic Scholar
Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers
Daehwan Kim, Heekyung Chung, Wen Liu, K. Jeong +25 more
2025npj Precision Oncology23 citations Open access
Semantic Scholar
PD-L1 tumor proportion score and overall survival from first-line pembrolizumab in patients with nonsquamous versus squamous non-small cell lung cancer
D. Doroshow, Wei Wei, Swati Gupta, J. Zugazagoitia +3 more
2021Journal of Thoracic Oncology22 citations Open access
Semantic Scholar
Clinical impact of COVID-19 on patients with cancer: Data from the COVID-19 and Cancer Consortium (CCC19).
J. Warner, S. Rubinstein, P. Grivas, T. Choueiri +16 more
2020Journal of Clinical Oncology21 citations
Semantic Scholar
C-reactive protein (CRP) as a prognostic biomarker in patients with urothelial carcinoma: A systematic review and meta-analysis
Yu Fujiwara, Alexander B. Karol, Himanshu Joshi, Emma Reford +3 more
2024Critical reviews in oncology/hematology18 citations Open access
Semantic Scholar
Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Jianhui Ma, Wen Liu, Jiali Li, Daehwan Kim +15 more
2025Molecular Cancer Therapeutics16 citations Open access
Semantic Scholar
Datopotamab deruxtecan (Dato-DXd) in locally advanced/metastatic urothelial cancer: Updated results from the phase 1 TROPIONPanTumor01 study.
F. Meric-Bernstam, O. Alhalabi, A. Lisberg, A. Drakaki +13 more
2025Journal of Clinical Oncology14 citations Open access
Semantic Scholar
Care disruptions among patients with lung cancer: A COVID-19 and cancer outcomes study
S. Bhalla, Z. Bakouny, A. Schmidt, C. Labaki +27 more
2021Lung Cancer14 citations Open access
Semantic Scholar
Phase 1 and phase 2a, first-in-human (FIH) study, of DRP-104, a broad glutamine antagonist, in adult patients with advanced solid tumors.
M. Johnson, D. Doroshow, T. Seiwert, M. Gibson +7 more
202114 citations
Semantic Scholar
Peripheral blood cytokines and outcomes with immune checkpoint blockade: a systematic review and meta-analysis.
Alexander B. Karol, Y. Fujiwara, T. D'Ovidio, E. Baldwin +3 more
2024Immunotherapy11 citations
Semantic Scholar
Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19
S. Gulati, Chih-Yuan Hsu, Surbhi Shah, Pankil Shah +50 more
2023JAMA Oncology9 citations Open access
Semantic Scholar
Phase II Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations
D. Doroshow, P. H. O'Donnell, J. Hoffman-Censits, Sumati V. Gupta +7 more
2023JCO Precision Oncology9 citations
Semantic Scholar
Predictive Biomarkers for Immune Checkpoint Inhibitors in Advanced Non–Small Cell Lung Cancer
S. Bhalla, D. Doroshow, F. Hirsch
2020Cancer Journal9 citations
Semantic Scholar
Trastuzumab emtansine: determining its role in management of HER2+ breast cancer.
D. Doroshow, P. LoRusso
2018Future Oncology8 citations
Semantic Scholar
The Room Where It Happens: Addressing Diversity, Equity, and Inclusion in NCTN Clinical Trial Leadership.
R. Snyder, B. Burtness, M. Cho, J. del Rivero +13 more
2023Journal of the National Cancer Institute7 citations Open access
Semantic Scholar
Abstract A080: Olaparib and the ATR inhibitor AZD6738 in relapsed, refractory cancer patients with homologous recombination (HR) repair mutations – OLAPCO
J. Eder, D. Sohal, H. Mahdi, K. Do +9 more
2019Clinical Trials7 citations
Semantic Scholar
Phase I study of BJ-001, a tumor-targeting interleukin-15 fusion protein, in patients with solid tumor.
K. Chung, Haeseong Park, R. Abdul-Karim, D. Doroshow +7 more
20216 citations
Semantic Scholar
From the Broad Phase II Trial to Precision Oncology: A Perspective on the Origins of Basket and Umbrella Clinical Trial Designs in Cancer Drug Development
D. Doroshow, J. Doroshow
2019Cancer Journal6 citations Open access
Semantic Scholar
Inpatient Immunotherapy Outcomes Study: A Multicenter Retrospective Analysis.
Fauzia Riaz, John L. Vaughn, Huili Zhu, J. Dickerson +12 more
2025JCO Oncology Practice5 citations
Semantic Scholar
Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing biliary tract cancer (BTC) and pancreatic cancer (PC): Outcomes from DESTINY-PanTumor02 (DP-02).
Do-Youn Oh, I. Lugowska, D. Stroyakovskiy, K. Jung +16 more
2024Journal of Clinical Oncology5 citations
Semantic Scholar
PD-L1 tumor proportion score and clinical benefit from first-line pembrolizumab in patients with advanced nonsquamous versus squamous non-small cell lung cancer (NSCLC).
D. Doroshow, Wei Wei, J. Zugazagoitia, C. J. Robbins +3 more
20205 citations
Semantic Scholar
Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Results from the bladder cohort of the DESTINY-PanTumor02 (DP-02) study.
P. Wysocki, K. Jung, Do-Youn Oh, D. Doroshow +13 more
2024Journal of Clinical Oncology4 citations
Semantic Scholar
A phase 1b/2 trial of dupilumab given in conjunction with PD-(L)1 blockade in the treatment of relapsed/refractory metastatic NSCLC.
Bailey G Fitzgerald, T. Marron, N. Hall, Daniel O'Grady +15 more
2022Journal of Clinical Oncology4 citations
Semantic Scholar
LBA74 Disparities in cancer during the COVID-19 pandemic: COVID-19 and cancer outcomes study (CCOS)
D. Doroshow, A. Schmidt, Z. Bakouny, S. Bhalla +16 more
2020Annals of Oncology4 citations Open access
Semantic Scholar
Trastuzumab deruxtecan (T-DXd) in pretreated patients (pts) with HER2-expressing bladder cancer: Final results from the bladder cancer cohort in Part 1 of DESTINY-PanTumor02 (DP-02).
Kyung Hae Jung, Do-Youn Oh, D. Doroshow, E. Artamonova +13 more
2026Journal of Clinical Oncology3 citations
Semantic Scholar
A randomized phase 3 study of ivonescimab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of metastatic non–small cell lung cancer: HARMONi-3.
Jian-Jun Zhang, Jun Cai, Hui Wang, Yan Yu +16 more
2025Journal of Clinical Oncology3 citations Open access
Semantic Scholar
C-reactive protein as a response biomarker to immune checkpoint blockade: A meta-analysis.
Alexander B. Karol, Y. Fujiwara, T. D'Ovidio, Elena Baldwin +3 more
2023Journal of Clinical Oncology2 citations
Semantic Scholar
Platinum Sensitivity in IDH1/2 Mutated Intrahepatic Cholangiocarcinoma: Not All “BRCAness” Is Created Equal
D. Doroshow, Wei Wei, M. Mehrotra, D. Sia +5 more
2023Cancer Investigation2 citations
Semantic Scholar
C-reactive protein (CRP) as a prognostic biomarker in patients with bladder cancer: A meta-analysis.
Y. Fujiwara, Alexander B. Karol, Emma Reford, Himanshu Joshi +2 more
2023Journal of Clinical Oncology2 citations Open access
Semantic Scholar
Abstract C030: HARMONi-3: A randomized, controlled, multiregional Phase 3 study of ivonescimab combined with chemotherapy versus pembrolizumab combined with chemotherapy for the first-line treatment of metastatic squamous non-small cell lung cancer
J. Riess, Shun Lu, J. Naidoo, Sara Kuruvilla +3 more
2023Molecular Cancer Therapeutics2 citations
Semantic Scholar
Abstract B040: NCI 10129: A Phase 2 Study of the PARP inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant advanced solid tumors
M. Cecchini, M. Pilat, N. Uboha, N. Azad +22 more
2023Molecular Cancer Therapeutics2 citations
Semantic Scholar
Mitotic Checkpoints and the Role of WEE1 Inhibition in Head and Neck Squamous Cell Carcinoma
Shihan N. Khan, P. Swiecicki, D. Doroshow
2022Cancer Journal2 citations
Semantic Scholar
Thrombotic complications with SARS-CoV-2 infection in patients with cancer on high-risk therapies: Data from the COVID-19 and Cancer Consortium (CCC19).
S. Gulati, Surbhi Shah, A. Kulkarni, A. Desai +16 more
2021Journal of Clinical Oncology2 citations
Semantic Scholar
Targeted therapy for DNA damage response and homologous recombination repair defects: The Olaparib Combinations trial
D. Doroshow, G. Shapiro, K. Do, Vicki L. Keedy +11 more
2026Cancer1 citations
Semantic Scholar
A phase 1b study of combined treatment with dupilumab (anti-IL-4Ra) and cemiplimab (anti-PD-1) in patients with early-stage, resectable NSCLC.
F. Crowley, Natalie Lucas, Kathy Wu, J. Wilk +16 more
2025Journal of Clinical Oncology1 citations Open access
Semantic Scholar
Assessing patient withdrawal in cancer clinical trials: A systematic evaluation of reasons and transparency in reporting.
A. Argulian, Alexander B. Karol, R. Paredes, Kasopefoluwa Y. Oguntuyo +6 more
2025Journal of Clinical Oncology1 citations
Semantic Scholar
Financial Toxicity Among Patients With Advanced Solid Tumors Participating in Early Phase Clinical Trials
J. Blanter, G. van Hyfte, Maham Ahmad, Suzanne Xu +17 more
2024JCO Oncology Practice1 citations Open access
Semantic Scholar
Abstract CT199: Rescuing response to ICI by blocking the type-2 immune axis in patients with NSCLC progressing on immunotherapy: A phase 1b/2 trial of dupilumab administered with checkpoint blockade
T. Marron, N. LaMarche, Matthew D. Park, Samarth Hegde +22 more
2023Cancer Research1 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Galsky×11
Invite
M. Galsky — researcher profile on SciRah
Z. Bakouny×9
Invite
Z. Bakouny — researcher profile on SciRah
A. Schmidt×7
Invite
A. Schmidt — researcher profile on SciRah
T. Choueiri×6
Invite
T. Choueiri — researcher profile on SciRah

×6

Invite

D. Shah — researcher profile on SciRah

Invite

P. Grivas — researcher profile on SciRah

Invite

G. Bouchard — researcher profile on SciRah

Invite

F. Busser — researcher profile on SciRah

Invite

C. Curran — researcher profile on SciRah

Invite

P. Nuzzo — researcher profile on SciRah

Invite

Y. Shyr — researcher profile on SciRah

Chih-Yuan Hsu×5

Invite

Chih-Yuan Hsu — researcher profile on SciRah